Skip to content
Bored Studies
RecruitingPhase 3

OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

Amgen · NCT07136012

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 50–105 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 3
Target enrollment
11000
US sites recruiting
194
Study start
August 22, 2025
Record last updated
August 21, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The primary objective is to evaluate the effect of olpasiran, compared to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants at risk for a first major cardiovascular event with elevated lipoprotein(a) (Lp[a]).

Being studied: Olpasiran; Placebo

Conditions: Cardiovascular Disease

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Age ≥50 years
  • Lp(a)≥ 200 nmol/L during screening
  • Multiple atherosclerotic cardiovascular disease risk factors, and/or evidence of atherosclerosis

Exclusion Criteria

  • Prior acute atherothrombotic event (myocardial infarction, stroke, transient ischemic attack, acute limb ischemia)
  • Prior or planned arterial revascularization
  • History of major bleeding disorder

Recruiting US locations

+ 134 more on the official record.

Study contacts (from the official record)

  • Amgen Call Center · 866-572-6436 · medinfo@amgen.com
All heart & blood pressure studies in Alabama →
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And… (NCT07136012) | Bored Studies